Alkermes

Alkermes Completes $2.1 Billion Acquisition of Avadel Pharmaceuticals

Alkermes has finalized its acquisition of Avadel Pharmaceuticals, bolstering its presence in the sleep medicine market.

Artificial Intelligence for New Drug Design

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.

Alkermes Announce Completion Of Merger Between Alkermes And Elan Drug Tech

Alkermes Q1 Loss Narrows Slightly